Aktie A102460 REYON PHARMACEUTICAL CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen REYON Pharmaceutical Co., Ltd.

Aktien

A102460

KR7102460003

A102460

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 04.07.2024 		% 5 Tage % 1. Jan.
13.330 KRW +0,76 % Intraday Chart für REYON Pharmaceutical Co., Ltd. -3,05 % -19,41 %
16.05. REYON Pharmaceutical Co. Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
21.03. REYON Pharmaceutical Co. Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
REYON Pharmaceutical Co., Ltd. announced that it has received KRW 10 billion in funding
REYON Pharmaceutical Co., Ltd. announced that it expects to receive KRW 10 billion in funding
Tranche Update on REYON Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 6, 2018.
REYON Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 6, 2018 has expired with 240,840 shares, representing 1.44% for KRW 4,975.65 million.
Tranche Update on REYON Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 6, 2018.
REYON Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
REYON Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
REYON Pharmaceutical Co., Ltd. announced that it has received KRW 40 billion in funding from Mirae Asset Daewoo Co., Ltd., KDB Capital Corp., Eum Private Equity, Industrial Bank of Korea, Investment Arm
REYON Pharmaceutical Co., Ltd. announced that it expects to receive KRW 40 billion in funding from Mirae Asset Daewoo Co., Ltd., KDB Capital Corp., Eum Private Equity, Industrial Bank of Korea, Investment Arm
REYON Pharmaceutical Co., Ltd.(KOSE:A102460) added to MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A102460 Aktie
  4. Nachrichten REYON Pharmaceutical Co., Ltd.
  5. Andere Sprachen